Landmark safety data support therapeutic angiogenesis
Safety evidence announced at the ESC Congress 2026 by Isomab has reinforced the potential of a new class of therapies designed to promote blood vessel growth as a disease-modifying approach for coronary artery disease (CAD). The systematic review of clinical trial data evaluating growth factor approaches, spanning… Read More